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Abstract
Purpose Positive surgical margin (PSM) status following
radical prostatectomy (RP) is a well-established prognostic
factor. The aim of the present study is to evaluate whether
number of PSMs or bilaterality of PSMs might have prog-
nostic signiWcance for biochemical recurrence (BCR) in the
population with a PSM status following RP.
Methods We evaluated 1,395 RP pathology reports from
our center between 1980 and 2006. All patients who under-
went (neo)-adjuvant therapy were excluded, leaving a
cohort of 1,009 patients, with 249 (24.7%) subjects having
a PSM at RP of whom 29.4% had multiple PSMs (¸ 2
sites), while 13.6% had bilateral PSMs. Median follow-up
was 40 months (range 0–258 months). We used BCR-free
survival as the primary study outcome. BCR was deWned as
any rise in PSA above or equal to 0.2 ng/ml.
Results Of patients with a PSM status, 41% (95% CI: 33–
49%) developed BCR within 5 years, compared to 12%
(95% CI: 9–15%) in the population without a PSM. Multi-
variable analysis identiWed PSA at diagnosis and RP Glea-
son score as independent predictive factors for BCR.
Increasing number and/or bilaterality of PSM did not lead
to signiWcant higher rates of BCR.
Conclusion In patients with a PSM, the number of posi-
tive sites or bilaterality of PSM status does not add prog-
nostic information for risk of BCR. Survival curve slopes
were diVerent for patients with bilateral PSM, showing a
signiWcant tendency to progress to BCR earlier during
follow-up than patients with unilateral PSM.
Keywords Prostate cancer · Surgical margin · 
Biochemical recurrence · Bilateral · Number · Prognosis
Introduction
The 5- and 10-year overall survival rates of radical prosta-
tectomy (RP) are excellent [1], leading to signiWcant sur-
vival beneWt compared to watchful waiting [2]. In the
absence of extraprostatic extension and positive surgical
margins (PSM), the rates of biochemical recurrence (BCR)
are low [3]. This does not stand true for patients with a
PSM, a common pathological feature following RP, with a
prevalence varying between 5 and 43% in diVerent series
[4, 5]. Several studies have shown PSM to be one of the
most important prognostic factors for BCR following radi-
cal prostatectomy [4–13].
The EORTC 22911 trial [14] established that adjuvant
external irradiation after RP improves biochemical recurrence
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(BCR)-free survival in patients with a PSM or pathological
T3 stage. Whether this translates into an overall survival
beneWt could not be detected due to a relative short follow-
up. In this trial, 43.7% of the patients in the wait-and-see
arm experienced biochemical or clinical progression or
death. This percentage was reduced to 26.1% in the irradia-
tion arm. However, if all patients in this series would have
received immediate radiotherapy, over Wfty percent would
have received intervention without ever progressing to
BCR at the cost of radiotherapeutic toxicity. Therefore,
characterization of patients at high risk of BCR after RP
would be of great help to identify those patients beneWting
most of immediate postoperative radiotherapy. Reevalua-
tion of the EORTC 22911 data by van der Kwast et al. [15]
stressed that among patients with adverse pathological fea-
tures on prostatectomy, those with PSM beneWt most from
immediate radiotherapy, preventing 291 BCR events for
every 1,000 treated. We hypothesized that the number of
PSMs or bilaterality of PSMs is an additional risk factor of
BCR in patients with a PSM and may indicate who will be
ideal candidates for adjuvant postoperative radiotherapy.
Patients and methods
Study population and data retrieval
The pathology reports of 1,395 open retropubic RP proce-
dures performed at the Department of Urology, Université
Catholique de Louvain, Brussels, between 1980 and 2006
by two surgeons were retrospectively evaluated for PSM
status. Since 1999, intra-operative frozen sections were
used to avoid PSMs. Patient and tumor characteristics were
retrospectively reviewed for all subjects with a PSM. All
subjects who were treated with neo-adjuvant and/or adju-
vant hormonal therapy or immediate postoperative radio-
therapy were excluded. Data on number and bilaterality of
PSM, as well as pathological stage, RP Gleason score and
the presence of perineural invasion (PNI) were obtained
from the original pathology reports. Charts were retrospec-
tively reviewed for PSA at diagnosis and follow-up data.
BCR was deWned as any rise in PSA (ng/ml) above or equal
to 0.2 ng/ml.
Pathology processing
The left and right sides of the prostate gland were identiWed
by a longitudinal incision into the right anterior half. Fol-
lowing Wxation in buVered 10% formaldehyde, the 5-mm-
thick proximal and distal transections of the prostate were
serially sectioned at 2-mm intervals parallel to the urethra.
The tips of the vasa deferentia were transected, and the
seminal vesicles were longitudinally sectioned up to their
junction with the prostate. The remaining prostate gland
was then serially sectioned perpendicularly to the apical–
basal axis at 5-mm intervals to perform whole mount sec-
tions. The external surface of surgical radical prostatectomy
specimens was covered with ink since 1990. Surgical mar-
gins were considered as positive or negative when the
malignant cells were separated without or with any amount
of benign tissue from the inked edge of the surgical resec-
tion of the gland, respectively. The paraYn-embedded tis-
sues were recut if necessary until visualization of the inked
margin. When the margins had not been inked, the paraYn
blocks were recut until the whole circumference of the tis-
sue sample was mounted on the slide. The edges of the arti-
factual disruptions of prostatic or extraprostatic tissue were
not considered as surgical margins.
Statistical analysis
For statistical analysis, we used SPSS software (SPSS, ver-
sion 16.0.01, Chicago, Illinois, USA). Kaplan–Meier sur-
vival analysis was performed with BCR-free survival as
outcome for both single versus multiple PSM and unilateral
versus bilateral PSM. The Wilcoxon test was used to detect
signiWcant diVerences in BCR-free survival rates between
groups. Multivariable Cox proportional hazards regression
models were composed to determine prognostic factors for
BCR. As multiple PSMs will represent a large subgroup of
bilateral PSMs, we performed multivariable analysis for
both factors separately. Statistical signiWcance in our study
was set at P < 0.05. With the numbers of single and multi-
ple PSM cases in our series, and an assumed 40% 5-year
risk of BCR, we had an 80% power to detect a hazard ratio
(HR) of 1.5. Likewise, we had a power of 80% of detecting
a HR of 1.7 for the comparison between unilateral and
bilateral PSM.
Results
We found suYcient data on surgical margin status for 1,314
patients to include them in our study. Of these, 378 (27.1%)
had one or more PSMs. Those who received immediate
postoperative radiotherapy (n = 181), neo-adjuvant
(n = 171), or adjuvant hormonal therapy (n =1 8 )  w e r e
excluded, leaving a cohort of 1,009 patients, with 249
(24.7%) subjects having one or more PSMs. Of 723
patients with a pT2 status, 122 (16.9%) had a PSM, com-
pared to 123 of 266 (46.2%) patients with a pT3 status, 8
patients had pT4 tumor, of which 4 had PSM (50.0%).
Seven patients had pT0 status upon RP, and in 5 patients,
the pathological stage could not be established. The median
follow-up was 40 months (range 0–258 months). We found
suYcient data on number of PSMs in 218/249 pathologyWorld J Urol (2012) 30:105–110 107
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reports; of these, 70.6% had a single PSM, while the
remaining 29.4% had two or more PSMs. In 191/249 sub-
jects, suYcient data were reported to determine PSM bilat-
erality; of these, 86.4% of the PSMs were unilateral and the
remaining 13.6% bilateral. Pathological stage diVered sig-
niWcantly between single and multiple PSM status
(P = 0.04) and unilateral versus bilateral PSM status
(P = 0.03), with patients with multiple or bilateral PSMs
having higher pathological stages. Age, PSA at diagnosis,
and RP Gleason score did not diVer signiWcantly among
groups. Table 1 summarizes all relevant patient characteris-
tics as identiWed in our series.
Overall, 41% (95% CI: 33–49%) of subjects with a PSM
developed a BCR within 5 years, compared to 12% (95%
CI: 9–15%) in the population without a PSM. When subdi-
vided into single and multiple PSMs, these percentages
were 43% (95% CI: 32–54%) versus 46% (95% CI: 31–
61%), respectively. Unilateral versus bilateral PSM
subjects had 5-year BCR rates of 45% (95% CI: 35–55%)
versus 46% (95% CI: 24–68%), respectively. Patients with
data missing on number of PSMs had a 5-year BCR rate of
24% (95% CI: 6–42%), while those with missing data on
bilaterality had a 5-year BCR rate of 30% (95% CI: 16–
44%). When we used the Wilcoxon test to detect diVer-
ences in the slope of the survival curves, we found that
survival curve slopes for unilateral versus bilateral PSM did
diVer signiWcantly (P = 0.029), as the bilateral PSM cohort
did progress to BCR earlier during follow-up, with the
curves closing in later on, see Fig. 1.
Univariable analysis identiWed PSA at diagnosis, patho-
logical stage, RP Gleason score, and perineural invasion
(PNI) as possible predictors of BCR after RP in this PSM
series, and these factors were consequently included in the
multivariable analysis. Bilateral PSM status and multiple
PSM status had no prognostic value for BCR on univariable
analysis. Multivariable analysis identiWed PSA at diagnosis
and RP Gleason score as independent prognostic factors for
BCR. Bilateral PSM status and number of PSMs did not
add prognostic information, see Table 2.
Discussion
Data on 5-year risk of BCR for PSM patients following RP
are reported between 25 and 47% [5, 10–12]. No eVect on
prostate cancer-speciWc survival or overall survival has been
determined for PSM status, probably because the available
follow-up does not suYce to detect these diVerences if pres-
ent. Preoperative PSA, RP Gleason score, and pathological
stage are well-established predictors of BCR following RP
[3, 16–19]. In correspondence with other series, we identi-
Wed RP Gleason score as a prognostic factor for BCR among
patients with a PSM [5, 7, 9, 11]. All these earlier reports
identiWed pathological stage as a prognostic factor for BCR
as well, which we could only conWrm in univariable analy-
sis. This might be contributed to the 370 patients that were
excluded from our analysis because of (neo)-adjuvant ther-
apy leading to a disproportional exclusion of poor-risk sub-
jects with higher pT stages. Furthermore, pT3 subjects were
more likely to have PSM, which was included in multivari-
able analysis, and might, due to its profound eVect on BCR
rates, diminish the eVect of pT3 stage on BCR rates. Much
debate remains over the prognostic value of PNI in RP spec-
imens [20, 21]. In our subset of patients with PSMs, we
could not identify PNI as an independent prognostic factor
for BCR on multivariable analysis.
Five studies address the number of PSMs in detail in
populations that did not receive immediate postoperative
Table 1 Patient characteristics
PSM positive surgical margin, SD standard deviation, CI conWdence interval, RP radical prostatectomy, BCR biochemical recurrence rate
Variable PSM Single PSM Multiple PSM Unilateral PSM Bilateral PSM
Number of subjects 249 154/218 (70.6%) 64/218 (29.4%) 165/191 (86.4%) 26/191 (13.6%)
Age (mean § SD) 63.8 § 6.9 63.6 § 6.9 64.7 § 6.1 63.8 § 6.5 64.3 § 7.0
PSA at diagnosis (mean § SD) 11.7 § 9.7 10.7 § 7.8 12.9 § 12.8 11.4 § 8.4 11.8 § 13.1
Pathological stage
pT2 122 (49.8%) 82 (53.9%) 25 (40.3%) 80 (49.7%) 10 (38.5%)
pT3 123 (50.2%) 70 (46.1%) 37 (59.7%) 81 (50.3%) 16 (61.5%)
Missing 4 2 2 4 0
RP Gleason score
·6 173 (69.8%) 110 (71.4%) 41 (64.1%) 118 (71.5%) 15 (57.7%)
7 66 (26.6%) 40 (26.0%) 18 (28.1%) 41 (24.8%) 9 (34.6%)
8–10 9 (3.6%) 4 (2.6%) 5 (7.8%) 6 (3.6%) 2 (7.7%)
Missing 1 0 0 0 0
5-year BCR (95% CI) 41% (33–49%) 43% (32–54%) 46% (31–61%) 45% (35–55%) 46% (24–68%)108 World J Urol (2012) 30:105–110
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therapy and yielded contradictory results. In a subset of 80
PSM patients analyzed by Lowe and Lieberman, a signiW-
cant increase in BCR for patients with multiple PSMs com-
pared with single PSM was found [22], a Wnding conWrmed
in another series by Sofer et al. with 210 patients with PSM
[23]. Both series did not include pathological stage in their
multivariable analyses which may have led to biased results
as one might hypothesize that extraprostatic extension (pT3)
is far more common in the subgroup with multiple PSM sta-
tus. In our series, we could conWrm that pathological T3
stage was signiWcantly more common in the multiple and
bilateral PSM cohorts compared with the single PSM cohort.
This hypothesis is supported by a larger series by Blute et al.
of 697 pT2 patients with a PSM in which only a slightly
Fig. 1 Kaplan–Meier BCR-free 
survival curves for unilateral and 
bilateral PSM
BCR: biochemical recurrence rate, PSM: positive surgical margin, F/U: follow-up.
0 6 8 4 6 3 4 2 2 1 0 h t n o M
Unilateral PSM cumulative number of events  0  16  31  42  47  51 
 remaining number  at  risk 165  134  92 65 45 28 
Bilateral PSM cumulative number of events  0  9  10  10  10  10 
 remaining number at risk  26  12  10  9  9  7 
Table 2 Univariable and multivariable analysis of prognostic factors for BCR in a PSM cohort
Values in italics are statistically signiWicant at P <0 . 0 5
BCR biochemical recurrence, PSM positive surgical margin, HR hazard ratio, CI conWdence interval, RP radical prostatectomy, PNI perineural
invasion, N/A not applicable




P-value Multivariable analysis 
HR (95% CI)
P-value
Age at RP 1.00 (0.97–1.03) N/A N/A N/A N/A
PSA at diagnosis (ng/ml) 1.04 (1.02–1.05) 1.03 (1.01–1.05) P = 0.002 1.04 (1.02–1.06) P = 0.000
Pathological stage (pT3 vs. pT2) 2.36 (1.47–3.79) 1.45 (0.82–2.58) P > 0.05 1.42 (0.77–2.63) P >0 . 0 5
RP Gleason score (per point) 1.42 (1.15–1.76) 1.34 (1.07–1.68) P = 0.01 1.32 (1.04–1.66) P = 0.02
PNI 2.20 (1.40–3.44) 1.22 (0.71–2.09) P > 0.05 1.43 (0.82–2.50) P >0 . 0 5
Multiple vs. single PSM 1.37 (0.72–2.64) 1.05 (0.63–1.74) P >0 . 0 5 N / A N / A
Bilateral vs. unilateral PSM 1.28 (0.79–2.07) N/A N/A 1.32 (0.66-2.62) P >0 . 0 5World J Urol (2012) 30:105–110 109
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higher rate of BCR was found for patients with multiple
PSM when compared with those with a single PSM [24].
Also, a more recent report on PSM status in 354 patients
with extraprostatic carcinoma (pT3a/b) on RP could also not
detect a signiWcant diVerence in BCR between patients with
single and multiple PSMs [11]. Therefore, we think that any
report on PSM status should include pathological stage in
the multivariable analysis in order to be able to assess the
independent prognostic value of PSM status properly. Fur-
thermore, as patients with multiple or bilateral PSMs tend to
experience BCR earlier during follow-up with Kaplan–
Meier curves closing in later on, the relative short follow-up
of 22 months by Sofer et al. [23] could lead to a false
impression of increased BCR for multiple PSMs when pro-
cessing Kaplan–Meier curves on these data. This is sup-
ported by the diVerence in calculated 5-year BCR rates for
multiple PSMs between ours and their series, 41% versus
approximately 60% (read from the Kaplan–Meier curve),
respectively. A series by Jayachandran et al. reporting on
902 patients with PSM and/or pT3 disease could not identify
pathological stage as an independent predictor of BCR on
univariable analysis, and thus, did not incorporate this factor
in their multivariable analysis [25]. Consequently, they
found number of PSM to be signiWcantly associated with
BCR on univariable and multivariable analysis, a Wnding we
could not conWrm. In their series, they did however exclude
a substantial number of patients (n = 205) with seminal vesi-
cle invasion, which could account for a large number of
BCR subjects in our series as these are relative poor-risk
subjects within the pT3 subgroup.
We did not take the extent or length and site of PSM into
account, and contradictory reports have been published on
this issue. Some Wnding length of PSM as a prognostic
marker for BCR [26], whereas others could not identify
extent of PSM as a prognostic marker [8, 27]. Most series
did not Wnd site of PSM to be predictive of BCR [23, 27],
while Blute et al. [24] identiWed the prostate base as the
only anatomic site of PSM predictive for recurrence at that
speciWc anatomic site with a signiWcant eVect on 5-year risk
of BCR, which increased from 15 to 44% in case of a PSM
at the prostate base.
To our knowledge, no study on bilaterality of PSM sta-
tus has been published before. Nevertheless, one might
hypothesize that bilateral PSM status might inXuence BCR-
free survival, as it might express more extensive tumor
involvement of the prostate bed after RP. Nevertheless, we
could not identify an independent prognostic value of bilat-
eral PSM status on multivariable analysis in our series. We
found patients with bilateral PSM to progress to BCR ear-
lier during follow-up, with survival curves closing in at
about 5-years of follow-up.
The main limitation of our series is the retrospective data
collection, which led to a substantial number of missing
data in which we could not establish the details of PSM sta-
tus on number and bilaterality. Interestingly, patients with
missing data did better as far as BCR rates are concerned,
which might be attributed to less detailed pathological
reporting on number and bilaterality of PSM in case of a sin-
gle or limited multiple PSM status. Another concern is the
relatively low power of our series to detect diVerences
between groups; this is mainly an issue in the comparison of
unilateral versus bilateral PSM, as only 26 subjects were
documented to have bilateral PSM. Furthermore, the median
follow-up of approximately 40 months could be insuYcient
to detect diVerences in long-term BCR in our series.
We conclude that number or bilaterality of PSM is not
independent predictors of BCR, although patients with
bilateral PSMs did show a signiWcant tendency to progress
to BCR earlier during follow-up compared to patients with
unilateral PSMs. For conclusive evidence, future prospec-
tive series with longer median follow-up addressing this
issue are needed. The search for more valid prognostic
markers for disease recurrence following RP continues for
better risk stratiWcation and decision making regarding tim-
ing of adjuvant radiotherapy in postprostatectomy subjects.
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